Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab monotherapy in previously treated advanced melanoma
NCT00289627Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2006
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Primary endpoint: Best Overall Response Rate. Started Apr 2006; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00289627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00289627.